1. Home
  2. NOTE vs KLRS Comparison

NOTE vs KLRS Comparison

Compare NOTE & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiscalNote Holdings Inc.

NOTE

FiscalNote Holdings Inc.

HOLD

Current Price

$1.90

Market Cap

39.9M

Sector

Technology

ML Signal

HOLD

Logo Kalaris Therapeutics Inc. Common Stock

KLRS

Kalaris Therapeutics Inc. Common Stock

HOLD

Current Price

$7.64

Market Cap

46.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOTE
KLRS
Founded
2013
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
46.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NOTE
KLRS
Price
$1.90
$7.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$29.25
$21.50
AVG Volume (30 Days)
238.6K
153.8K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$102,673,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.83
$2.14
52 Week High
$24.36
$12.90

Technical Indicators

Market Signals
Indicator
NOTE
KLRS
Relative Strength Index (RSI) 27.09 70.41
Support Level $1.88 $5.58
Resistance Level $2.15 $6.27
Average True Range (ATR) 0.19 0.70
MACD 0.04 0.10
Stochastic Oscillator 10.88 98.08

Price Performance

Historical Comparison
NOTE
KLRS

About NOTE FiscalNote Holdings Inc.

FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: